- GC Biopharma and the Thai Red Cross Society have signed a Memorandum of Understanding to strengthen collaboration in plasma-derived therapies.
- The agreement includes training and technology transfer programmes to expand Thailand’s capacity in plasma fractionation and workforce development.
GC Biopharma has signed a Memorandum of Understanding (MOU) with the Thai Red Cross Society (TRCS) to enhance cooperation in plasma-derived therapies. The agreement was signed on 14 August 2025.
The new partnership builds on collaboration dating back to 2015, when GC Biopharma supported the establishment of Thailand’s plasma fractionation facility. Under the MOU, the parties will develop training and exchange programmes to transfer advanced manufacturing technologies and strengthen local capabilities for plasma-derived medicinal product production.
Vice President Hyoungjun Park said, “This MOU is a vital step in expanding advanced technology across Asia while contributing to public welfare.” Assoc. Prof. Dootchai Chaiwanichsiri, Director of the National Blood Centre, TRCS, highlighted the importance of the collaboration for human resource development and technology transfer.
The partnership is expected to support workforce development, improve product quality and safety, and contribute to public health security in Thailand and the wider region.
GC Biopharma noted that the agreement reflects its broader strategy to expand its plasma-derived therapeutics business. The company entered the U.S. immunoglobulin market in 2024 and continues to pursue partnerships in Southeast Asia, where domestic fractionation capacity is developing.
